Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ewing tumors in infants.

Henk van den Berg1, Uta Dirksen, Andreas Ranft

  • 1Department of Pediatric Oncology, Emma Children Hospital, Academic Medical Center, University of Amsterdamm, The Netherlands. h.vandenberg@amc.uva.nl

Pediatric Blood & Cancer
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of standardized uptake value (SUV) and apparent diffusion coefficient (ADC) as prognostic imaging parameters for primary Ewing sarcoma in hybrid 18F-FDG-PET/MRI.

European journal of radiology·2026
Same author

Diagnostic value of integrated 18F-fluorodeoxyglucose PET/MRI in initial staging and recurrence detection of Ewing sarcoma.

Nuclear medicine communications·2026
Same author

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology·2026
Same author

Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Potential biomarkers of Ewing sarcoma identified through a Europe-wide analysis of prospectively collected samples.

Scientific reports·2026
Same author

Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma models.

Scientific reports·2026
Same journal

Comment on: "The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience"-The Evolving Role of the BIT Regimen.

Pediatric blood & cancer·2026
Same journal

Extramedullary Intradural Spinal Tumor in an Infant With Neurocutaneous Melanosis.

Pediatric blood & cancer·2026
Same journal

The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia.

Pediatric blood & cancer·2026
Same journal

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Pediatric blood & cancer·2026
Same journal

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
Same journal

Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
See all related articles

Infants diagnosed with Ewing family tumors, often peripheral neuroectodermal tumors (PNETs), show similar outcomes to older patients. This suggests that typical poor prognostic factors do not impact infant outcomes for these rare childhood cancers.

Area of Science:

  • Pediatric Oncology
  • Rare Childhood Cancers
  • Ewing Sarcoma Family of Tumors

Background:

  • Malignancies in infancy are exceptionally rare, with Ewing tumors being particularly uncommon.
  • Existing assumptions suggest a poor prognosis for infant malignancies.

Purpose of the Study:

  • To investigate the outcomes of Ewing family tumors in infants.
  • To determine if infants with these rare tumors face a poorer prognosis compared to older children.

Main Methods:

  • A cohort of 14 infants (<12 months) with Ewing family tumors was identified from multiple international databases (CESS81, CESS86, EICESS92, EuroEwing99).
  • Tumor characteristics, treatment modalities, and patient outcomes were analyzed.

Main Results:

Related Experiment Videos

  • The majority of infant tumors were peripheral neuroectodermal tumors (PNETs), predominantly axial.
  • Treatment protocols and dose reductions were comparable to older patients.
  • Achieved 5-year event-free survival (EFS) of 65% and overall survival (OS) of 72%, similar to older age groups.

Conclusions:

  • Infants with Ewing family tumors are typically diagnosed with PNETs, often presenting as axial tumors.
  • The prognosis for infants with Ewing family tumors is comparable to that of older patients.
  • Commonly accepted adverse prognostic factors did not significantly affect outcomes in this infant cohort.